RU2014141114A - Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина - Google Patents
Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина Download PDFInfo
- Publication number
- RU2014141114A RU2014141114A RU2014141114A RU2014141114A RU2014141114A RU 2014141114 A RU2014141114 A RU 2014141114A RU 2014141114 A RU2014141114 A RU 2014141114A RU 2014141114 A RU2014141114 A RU 2014141114A RU 2014141114 A RU2014141114 A RU 2014141114A
- Authority
- RU
- Russia
- Prior art keywords
- agent
- pharmaceutical composition
- cadherin
- inhibits
- secad
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 24
- 239000012634 fragment Substances 0.000 claims abstract 17
- 102000000905 Cadherin Human genes 0.000 claims abstract 15
- 108050007957 Cadherin Proteins 0.000 claims abstract 15
- 201000011510 cancer Diseases 0.000 claims abstract 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract 6
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims abstract 5
- 102000001301 EGF receptor Human genes 0.000 claims abstract 5
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims abstract 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract 5
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims abstract 5
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims abstract 5
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims abstract 5
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims abstract 5
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims abstract 5
- 108091008605 VEGF receptors Proteins 0.000 claims abstract 4
- 230000003211 malignant effect Effects 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 4
- 102000005962 receptors Human genes 0.000 claims abstract 4
- 108020003175 receptors Proteins 0.000 claims abstract 4
- 229960005395 cetuximab Drugs 0.000 claims abstract 3
- 229960001972 panitumumab Drugs 0.000 claims abstract 3
- 229960000575 trastuzumab Drugs 0.000 claims abstract 3
- 108091008815 Eph receptors Proteins 0.000 claims abstract 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims abstract 2
- 108091008553 MuSK receptors Proteins 0.000 claims abstract 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims abstract 2
- 108091008551 RET receptors Proteins 0.000 claims abstract 2
- 102000005450 TIE receptors Human genes 0.000 claims abstract 2
- 108010006830 TIE receptors Proteins 0.000 claims abstract 2
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims abstract 2
- 125000000539 amino acid group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 12
- 230000000890 antigenic effect Effects 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 230000019491 signal transduction Effects 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 102000038030 PI3Ks Human genes 0.000 claims 3
- 108091007960 PI3Ks Proteins 0.000 claims 3
- 102000004584 Somatomedin Receptors Human genes 0.000 claims 3
- 108010017622 Somatomedin Receptors Proteins 0.000 claims 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 239000000092 prognostic biomarker Substances 0.000 claims 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 3
- LSFLAQVDISHMNB-UHFFFAOYSA-N 5-(3-phenylmethoxyphenyl)-7-[3-(pyrrolidin-1-ylmethyl)cyclobutyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CC(CN3CCCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 LSFLAQVDISHMNB-UHFFFAOYSA-N 0.000 claims 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 2
- 102000043136 MAP kinase family Human genes 0.000 claims 2
- 108091054455 MAP kinase family Proteins 0.000 claims 2
- 108010081667 aflibercept Proteins 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 210000004994 reproductive system Anatomy 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 2
- 229960000241 vandetanib Drugs 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 229960002760 ziv-aflibercept Drugs 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000005001 male reproductive tract Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 abstract 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611390P | 2012-03-15 | 2012-03-15 | |
| US61/611,390 | 2012-03-15 | ||
| US201261736475P | 2012-12-12 | 2012-12-12 | |
| US61/736,475 | 2012-12-12 | ||
| PCT/US2013/032656 WO2013138790A1 (en) | 2012-03-15 | 2013-03-15 | Combination therapies including inhibitors of the extracellular domain of e-cadherin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014141114A true RU2014141114A (ru) | 2016-05-10 |
Family
ID=49161879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014141114A RU2014141114A (ru) | 2012-03-15 | 2013-03-15 | Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150037354A1 (enExample) |
| EP (1) | EP2844270A4 (enExample) |
| JP (1) | JP2015514062A (enExample) |
| KR (1) | KR20140138956A (enExample) |
| CN (1) | CN104519899A (enExample) |
| CA (1) | CA2867456A1 (enExample) |
| RU (1) | RU2014141114A (enExample) |
| WO (1) | WO2013138790A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2895623B1 (en) | 2012-09-17 | 2018-08-22 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
| EP2922832B1 (en) | 2012-11-21 | 2019-10-09 | Agios Pharmaceuticals, Inc. | Glutaminase inhibitors and methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| BR112016021620A2 (pt) | 2014-03-21 | 2018-07-10 | Agios Pharmaceuticals Inc | compostos e seus métodos de uso |
| ES2732925T3 (es) * | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
| CN111208283B (zh) * | 2018-11-21 | 2023-09-26 | 中国科学院分子细胞科学卓越创新中心 | 增效的肿瘤抑制组合物及其应用 |
| CN115040695B (zh) * | 2021-03-09 | 2023-10-13 | 南开大学 | 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT414097B (de) * | 2004-06-25 | 2006-09-15 | Petzelbauer Peter Dr | Pharmazeutische zubereitung zur behandlung von schock |
| CN102753579A (zh) * | 2009-05-01 | 2012-10-24 | 国立大学法人东京大学 | 抗钙粘着蛋白抗体 |
| AU2011319777B2 (en) * | 2010-10-27 | 2016-12-08 | The Research Foundation For The State University Of New York | Compositions targeting the soluble extracellular domain of E-cadherin and related methods for cancer therapy |
-
2013
- 2013-03-15 WO PCT/US2013/032656 patent/WO2013138790A1/en not_active Ceased
- 2013-03-15 CN CN201380024208.0A patent/CN104519899A/zh active Pending
- 2013-03-15 EP EP13760736.2A patent/EP2844270A4/en not_active Withdrawn
- 2013-03-15 US US14/385,351 patent/US20150037354A1/en not_active Abandoned
- 2013-03-15 CA CA2867456A patent/CA2867456A1/en not_active Abandoned
- 2013-03-15 RU RU2014141114A patent/RU2014141114A/ru not_active Application Discontinuation
- 2013-03-15 KR KR1020147028934A patent/KR20140138956A/ko not_active Withdrawn
- 2013-03-15 JP JP2015500673A patent/JP2015514062A/ja active Pending
-
2018
- 2018-01-29 US US15/882,513 patent/US20190008957A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015514062A (ja) | 2015-05-18 |
| EP2844270A4 (en) | 2016-01-27 |
| US20190008957A1 (en) | 2019-01-10 |
| CA2867456A1 (en) | 2013-09-19 |
| CN104519899A (zh) | 2015-04-15 |
| KR20140138956A (ko) | 2014-12-04 |
| EP2844270A1 (en) | 2015-03-11 |
| US20150037354A1 (en) | 2015-02-05 |
| WO2013138790A1 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014141114A (ru) | Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина | |
| Rajaram et al. | Epidermal growth factor receptor: Role in human cancer | |
| Mackay et al. | A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND. 184 | |
| Cao et al. | Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway | |
| Joshi et al. | Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells | |
| AU2019226270B2 (en) | Methods and compositions for prognosis, diagnosis and treatment of ADAM8-expressing cancer | |
| Fan et al. | Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway | |
| CN110194787B (zh) | 靶向抑制Wnt/β-catenin信号活性的多肽及其用途 | |
| JP2015514062A5 (enExample) | ||
| Yan et al. | Cancer-associated fibroblasts promote lymphatic metastasis in cholangiocarcinoma via the PDGF-BB/PDGFR-β mediated paracrine signaling network | |
| RU2013123792A (ru) | Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний | |
| Weng et al. | RON and MET co-overexpression are significant pathological characteristics of poor survival and therapeutic targets of tyrosine kinase inhibitors in triple-negative breast cancer | |
| Mehta et al. | Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage | |
| CN103201290A (zh) | S100a4抗体及其治疗用途 | |
| Gourgue et al. | Obesity and triple‐negative‐breast‐cancer: Is apelin a new key target? | |
| KR101215069B1 (ko) | Ｇｋｎ １을 함유하는 항암용 조성물 | |
| ES2328159T3 (es) | Inmunoglobulinas anti-epcam. | |
| Chou et al. | Regulation of extracellular and intracellular prolactin on cell proliferation and survival rate through GHR/JAK2/STAT3 pathway in NSCLC | |
| EP2984108A1 (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer | |
| CN110064045A (zh) | 微肽cip2a-bp在治疗癌症中的应用 | |
| Yotsumoto et al. | Efficacy of ligand-based targeting for the EGF system in cancer | |
| WO2019233469A1 (zh) | Pdgfr信号通路抑制剂用于制备治疗肠道炎症疾病的药物方面的用途 | |
| TWI842966B (zh) | 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途 | |
| Ahmed et al. | Potential effect of Imatinib on some sex hormones for male patients of Chronic Myelogenous Leukemia in Baghdad province | |
| Schultz et al. | Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180112 |